First-Line Antituberculosis Drug Concentrations in Infants With HIV and a History of Recent Admission With Severe Pneumonia

Chishala Chabala,Tom G. Jacobs, Cinta Moraleda, John M. Ndaferankhande,Vivian Mumbiro, Alfeu Passanduca, Natasha Namuziya,Damalie Nalwanga, Victor Musiime, Alvaro Ballesteros, Sara Dominguez-Rodriguez,Moses Chitsamatanga, Uneisse Cassia, Bwendo Nduna, Justina Bramugy, Jahit Sacarlal, Lola Madrid, Kusum J. Nathoo,Angela Colbers, David M. Burger, Veronica Mulenga, W. Chris Buck, Hilda A. Mujuru, Lindsey H. M. te Brake, Pablo Rojo, Alfredo Tagarro,Rob E. Aarnoutse, Muhammad Sidat

JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY(2023)

引用 0|浏览14
暂无评分
摘要
Optimal antituberculosis therapy is essential for favorable clinical outcomes. Peak plasma concentrations of first-line antituberculosis drugs in infants with living HIV receiving WHO-recommended dosing were low compared with reference values for adults, supporting studies on increased doses of first-line TB drugs in infants. First-line antituberculosis drug peak concentrations in infants with HIV were low compared with reference values for adults. The percent peak concentrations within adult reference values were 51%, 22%, 76%, and 6% for isoniazid, rifampicin, pyrazinamide, and ethambutol, respectively.
更多
查看译文
关键词
HRZE,Tuberculosis,HIV,pharmacokinetics,infants
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要